A Feasibility Study Evaluating rhBMP-2/Absorbable Collagen Sponge for Maxillary Sinus Floor Augmentation

Philip J. Boyne, Robert Marx, Myron Nevins, Gilbert Triplett, Emmanuel Lazaro, Leslie C. Lilly, Marden Alder, Pirkka Nummikoski

Research output: Contribution to journalArticle

393 Citations (Scopus)

Abstract

This 16-week open-label study assessed the safety and technical feasibility of implanting human recombinant bone morphogenetic protein-2 delivered on an absorbable collagen sponge (rhBMP-2/ACS) for two-stage maxillary floor sinus augmentation. This first use of rhBMP-2/ACS In human clinical maxillary sinus floor augmentation included 12 patients with inadequate bone height in the posterior maxilla. The total delivered dose ofrhBMP-2 implanted varied from 1.77 to 3.40 mg per patient. The rhBMP-2/ACS device was easily handled. Significant bone growth was documented by computerized tomographic scans in all evaluable patients (11/12). The overall mean height response for the maxillary sinus floor augmentation was 8.51 mm (95% confidence interval 6.07 to 10.95). There were no serious or unexpected immunologic or adverse effects and no clinically significant changes in complete blood counts, blood chemistries, or urinalysis results. The most frequent adverse effects were facial edema, oral erythema, pain, and rhinitis. Eleven patients have received dental implants and follow-up examinations are still being conducted. Histologic examinations of core bone biopsies obtained at the time of dental implant placement confirmed the quality of the bone induced by rhBMP-2/ACS. These results tend to indicate that rhBMP-2/ACS may provide an acceptable alternative to traditional bone grafts and bone substitutes for maxillary sinus floor augmentation procedures in humans.

Original languageEnglish
Pages (from-to)11-25
Number of pages15
JournalInternational Journal of Periodontics and Restorative Dentistry
Volume17
Issue number1
StatePublished - Dec 1 1997

Fingerprint

Sinus Floor Augmentation
Feasibility Studies
Porifera
Collagen
Bone and Bones
Dental Implants
Bone Substitutes
Urinalysis
Blood Cell Count
Bone Development
Maxilla
Erythema
Rhinitis
Edema
Confidence Intervals
Transplants
Biopsy
Safety
Pain
Equipment and Supplies

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

A Feasibility Study Evaluating rhBMP-2/Absorbable Collagen Sponge for Maxillary Sinus Floor Augmentation. / Boyne, Philip J.; Marx, Robert; Nevins, Myron; Triplett, Gilbert; Lazaro, Emmanuel; Lilly, Leslie C.; Alder, Marden; Nummikoski, Pirkka.

In: International Journal of Periodontics and Restorative Dentistry, Vol. 17, No. 1, 01.12.1997, p. 11-25.

Research output: Contribution to journalArticle

Boyne, PJ, Marx, R, Nevins, M, Triplett, G, Lazaro, E, Lilly, LC, Alder, M & Nummikoski, P 1997, 'A Feasibility Study Evaluating rhBMP-2/Absorbable Collagen Sponge for Maxillary Sinus Floor Augmentation', International Journal of Periodontics and Restorative Dentistry, vol. 17, no. 1, pp. 11-25.
Boyne, Philip J. ; Marx, Robert ; Nevins, Myron ; Triplett, Gilbert ; Lazaro, Emmanuel ; Lilly, Leslie C. ; Alder, Marden ; Nummikoski, Pirkka. / A Feasibility Study Evaluating rhBMP-2/Absorbable Collagen Sponge for Maxillary Sinus Floor Augmentation. In: International Journal of Periodontics and Restorative Dentistry. 1997 ; Vol. 17, No. 1. pp. 11-25.
@article{4eca1ac6090f4da0b69b7322b6d6aed8,
title = "A Feasibility Study Evaluating rhBMP-2/Absorbable Collagen Sponge for Maxillary Sinus Floor Augmentation",
abstract = "This 16-week open-label study assessed the safety and technical feasibility of implanting human recombinant bone morphogenetic protein-2 delivered on an absorbable collagen sponge (rhBMP-2/ACS) for two-stage maxillary floor sinus augmentation. This first use of rhBMP-2/ACS In human clinical maxillary sinus floor augmentation included 12 patients with inadequate bone height in the posterior maxilla. The total delivered dose ofrhBMP-2 implanted varied from 1.77 to 3.40 mg per patient. The rhBMP-2/ACS device was easily handled. Significant bone growth was documented by computerized tomographic scans in all evaluable patients (11/12). The overall mean height response for the maxillary sinus floor augmentation was 8.51 mm (95{\%} confidence interval 6.07 to 10.95). There were no serious or unexpected immunologic or adverse effects and no clinically significant changes in complete blood counts, blood chemistries, or urinalysis results. The most frequent adverse effects were facial edema, oral erythema, pain, and rhinitis. Eleven patients have received dental implants and follow-up examinations are still being conducted. Histologic examinations of core bone biopsies obtained at the time of dental implant placement confirmed the quality of the bone induced by rhBMP-2/ACS. These results tend to indicate that rhBMP-2/ACS may provide an acceptable alternative to traditional bone grafts and bone substitutes for maxillary sinus floor augmentation procedures in humans.",
author = "Boyne, {Philip J.} and Robert Marx and Myron Nevins and Gilbert Triplett and Emmanuel Lazaro and Lilly, {Leslie C.} and Marden Alder and Pirkka Nummikoski",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "17",
pages = "11--25",
journal = "International Journal of Periodontics and Restorative Dentistry",
issn = "0198-7569",
publisher = "Quintessence Publishing Company",
number = "1",

}

TY - JOUR

T1 - A Feasibility Study Evaluating rhBMP-2/Absorbable Collagen Sponge for Maxillary Sinus Floor Augmentation

AU - Boyne, Philip J.

AU - Marx, Robert

AU - Nevins, Myron

AU - Triplett, Gilbert

AU - Lazaro, Emmanuel

AU - Lilly, Leslie C.

AU - Alder, Marden

AU - Nummikoski, Pirkka

PY - 1997/12/1

Y1 - 1997/12/1

N2 - This 16-week open-label study assessed the safety and technical feasibility of implanting human recombinant bone morphogenetic protein-2 delivered on an absorbable collagen sponge (rhBMP-2/ACS) for two-stage maxillary floor sinus augmentation. This first use of rhBMP-2/ACS In human clinical maxillary sinus floor augmentation included 12 patients with inadequate bone height in the posterior maxilla. The total delivered dose ofrhBMP-2 implanted varied from 1.77 to 3.40 mg per patient. The rhBMP-2/ACS device was easily handled. Significant bone growth was documented by computerized tomographic scans in all evaluable patients (11/12). The overall mean height response for the maxillary sinus floor augmentation was 8.51 mm (95% confidence interval 6.07 to 10.95). There were no serious or unexpected immunologic or adverse effects and no clinically significant changes in complete blood counts, blood chemistries, or urinalysis results. The most frequent adverse effects were facial edema, oral erythema, pain, and rhinitis. Eleven patients have received dental implants and follow-up examinations are still being conducted. Histologic examinations of core bone biopsies obtained at the time of dental implant placement confirmed the quality of the bone induced by rhBMP-2/ACS. These results tend to indicate that rhBMP-2/ACS may provide an acceptable alternative to traditional bone grafts and bone substitutes for maxillary sinus floor augmentation procedures in humans.

AB - This 16-week open-label study assessed the safety and technical feasibility of implanting human recombinant bone morphogenetic protein-2 delivered on an absorbable collagen sponge (rhBMP-2/ACS) for two-stage maxillary floor sinus augmentation. This first use of rhBMP-2/ACS In human clinical maxillary sinus floor augmentation included 12 patients with inadequate bone height in the posterior maxilla. The total delivered dose ofrhBMP-2 implanted varied from 1.77 to 3.40 mg per patient. The rhBMP-2/ACS device was easily handled. Significant bone growth was documented by computerized tomographic scans in all evaluable patients (11/12). The overall mean height response for the maxillary sinus floor augmentation was 8.51 mm (95% confidence interval 6.07 to 10.95). There were no serious or unexpected immunologic or adverse effects and no clinically significant changes in complete blood counts, blood chemistries, or urinalysis results. The most frequent adverse effects were facial edema, oral erythema, pain, and rhinitis. Eleven patients have received dental implants and follow-up examinations are still being conducted. Histologic examinations of core bone biopsies obtained at the time of dental implant placement confirmed the quality of the bone induced by rhBMP-2/ACS. These results tend to indicate that rhBMP-2/ACS may provide an acceptable alternative to traditional bone grafts and bone substitutes for maxillary sinus floor augmentation procedures in humans.

UR - http://www.scopus.com/inward/record.url?scp=0031061210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031061210&partnerID=8YFLogxK

M3 - Article

C2 - 10332250

AN - SCOPUS:0031061210

VL - 17

SP - 11

EP - 25

JO - International Journal of Periodontics and Restorative Dentistry

JF - International Journal of Periodontics and Restorative Dentistry

SN - 0198-7569

IS - 1

ER -